← Patent-cliff monitor small molecule OPZELURA RUXOLITINIB PHOSPHATE
Loss of exclusivity May 2041 latest FDA-listed patent expiry
Company Incyte → See this company's full patent-cliff portfolio Drug detail Brand name OPZELURA Active ingredient RUXOLITINIB PHOSPHATE Strength EQ 1.5% BASE Dosage form CREAM Route TOPICAL Modality Small molecule FDA approval September 2021 Marketing status RX
Listed patents Patent Expires Type 11602536 May 2041 use U-3550 11590137 September 2040 use U-3505 11510923 September 2040 use U-3505 12589096 September 2040 use U-3505 12233067 July 2040 use U-4151 11590138 June 2040 use U-3551 11219624*PED November 2031 — 10758543*PED November 2031 — 10869870*PED November 2031 — 12544381 May 2031 product 10869870 May 2031 use U-3229 11219624 May 2031 product 11590136 May 2031 use U-3404 12564593 May 2031 product 10758543 May 2031 product 12226419 May 2031 product 11571425 May 2031 product 8822481*PED December 2028 — 10610530*PED December 2028 — 8722693*PED December 2028 — 7598257*PED June 2028 — 8415362*PED June 2028 — 8822481 June 2028 use U-3229 10610530 June 2028 use U-3229 8722693 June 2028 substance, product 8415362 December 2027 substance, product 7598257 December 2027 substance, product 9974790*PED June 2027 — 10639310*PED June 2027 — 9079912*PED June 2027 — 9079912 December 2026 use U-3229 10639310 December 2026 use U-3229 9974790 December 2026 use U-3229
Regulatory exclusivity Code Expires NPP September 2028 PED January 2026 I-896 July 2025
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.